CoV-2 Spike (318-542)
Escherichia Coli.
Sterile Filtered clear solution.
Protein is >95% pure as determined by 10% PAGE (coomassie staining).
Description
Recombinant Coronavirus 2019 Spike Receptor Binding Domain (318-542 aa) having a Mw of 25.7kDa was purified from E. coli.
The CoV-2 Spike is fused to a 6xHis tag at its C terminal and purified by proprietary chromatographic technique.
Product Specs
First identified in Wuhan, China, in December 2019, the 2019 novel coronavirus (2019-nCoV) is a human coronavirus responsible for causing viral pneumonia. Genetic analysis reveals that 2019-nCoV shares 87% of its identity with the bat-derived severe acute respiratory syndrome coronavirus (SARS-CoV-2) discovered in Zhoushan, eastern China, in 2018. Despite some differences, the receptor-binding domain (RBD) structure of 2019-nCoV is similar to that of 2018 SARS-CoV, suggesting that 2019-nCoV may also bind to the human angiotensin-converting enzyme 2 (ACE2) receptor. While bats are considered the likely natural reservoir of 2019-nCoV, an intermediate animal host, potentially from the seafood market in Wuhan, is suspected. Research suggests that 2019-nCoV may be a recombinant virus, with its spike glycoprotein exhibiting elements from both bat coronaviruses and an unknown coronavirus.
This product consists of the recombinant Coronavirus 2019 Spike Receptor Binding Domain (amino acids 318-542), with a molecular weight of 25.7 kDa. Expressed in E. coli, this protein features a C-terminal 6xHis tag and undergoes purification via a proprietary chromatographic method.
Sterile Filtered clear solution.
The CoV-2 Spike protein solution is formulated in PBS (phosphate-buffered saline) with 25mM K2CO3 (potassium carbonate).
For short-term storage (up to 4 weeks), the product can be stored at 4°C. For extended storage, freezing at -20°C is recommended. To further enhance long-term stability, the addition of a carrier protein (0.1% HSA or BSA) is advisable. Minimize freeze-thaw cycles to maintain product integrity.
The purity of the protein is determined to be greater than 95% based on 10% SDS-PAGE analysis with Coomassie blue staining.
This product is suitable for various applications, including ELISA (enzyme-linked immunosorbent assay), Western blot analysis, and lateral flow immunoassays.
Escherichia Coli.
HMRVQPTESI VRFPNITNLC PFGEVFNATR FASVYAWNRK RISNCVADYS VLYNSASFS TFKCYGVSPT KLNDLCFTNV YADSFVIRGD EVRQIAPGQT GKIADYNYKL PDDFTGCVI AWNSNNLDSKV GGNYNYLYRL FRKSNLKPFE RDISTEIYQA GSTPCNGVEG FNCYFPLQSY GFQPTNGVGY QPYRVVVLSF ELLHAPATVC GPKKSTNLVK NKCVNFNLE
Product Science Overview
The Coronavirus 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has led to extensive research into its structure and mechanisms of infection. One of the critical components of SARS-CoV-2 is the spike (S) protein, which facilitates the virus’s entry into host cells. The spike protein contains a specific region known as the Receptor Binding Domain (RBD), which is crucial for binding to the host cell receptor, angiotensin-converting enzyme 2 (ACE2).
The RBD of the SARS-CoV-2 spike protein spans amino acids 318 to 542. This domain is responsible for the initial interaction with the ACE2 receptor on the surface of host cells. The binding of the RBD to ACE2 is a key step in the viral entry process, allowing the virus to fuse with the host cell membrane and release its genetic material into the cell .
Recombinant RBD refers to the RBD produced through recombinant DNA technology. This involves inserting the gene encoding the RBD into an expression system, such as bacteria, yeast, or mammalian cells, to produce the protein in large quantities. Recombinant RBD is used in various applications, including vaccine development, diagnostic assays, and therapeutic research.
The RBD is a prime target for vaccine development due to its critical role in viral entry. Vaccines that elicit an immune response against the RBD can potentially block the virus from binding to ACE2, thereby preventing infection. Several COVID-19 vaccines, including mRNA vaccines, have been designed to induce antibodies against the RBD .
Recombinant RBD is also used in diagnostic assays to detect antibodies against SARS-CoV-2 in patient samples. These assays help determine whether an individual has been exposed to the virus and has developed an immune response. Additionally, recombinant RBD is being explored as a therapeutic agent. For example, it can be used to develop monoclonal antibodies that specifically target the RBD, neutralizing the virus and preventing it from infecting cells .
